Connected Thinking

Leading Voices

Latest News

‘Great Urgency’ to Understand KRAS as an Actionable Marker in Lung Cancer

As cancer treatment evolves into precision medicine, certain markers are emerging as actionable targets for therapy, including G12C inhibitors for the KRAS gene. KRAS is considered to be the most mutated oncogene in human cancers. At least three different mutations in this gene are associated with lung cancer.

Learn More

Is a CT Scan Always Needed After Chemoradiation for Lung Cancer?

For patients with stage IIIB non-small cell lung cancer (NSCLC), treatment may start with chemoradiation. If the cancer remains under control after two or three of these treatments, durvalumab (brand name: Imfinzi) therapy can help keep it from progressing. Is it always necessary to do a post-treatment CT scan before prescribing Imfinzi?

Learn More

Importance of Monitoring Lung Cancer Patients on Imfinzi for Possible Pneumonitis

Durvalumab (brand name: Imfinzi) is the standard of care following chemoradiation for patients with stage III unresectable lung cancer. Patients who receive this and other checkpoint inhibitors will need careful monitoring for potential adverse immune events.

Learn More

Immune Therapies — The Future of Acute Lymphoblastic Leukemia Treatment

We have entered a new era of acute lymphoblastic leukemia (ALL) therapy. Targeted treatments use the patients’ own immune system to attack the cancer, and in the process, possibly avoid some of the side effects of chemotherapy. Three therapies in particular are having a significant impact on the treatment of ALL patients who have relapsed.

Learn More

CAR T-Cell Therapy in Acute Lymphoblastic Leukemia May Achieve ‘Deep Remission’

The chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (brand name: Kymriah) is an FDA-approved treatment for children and young adults with relapsed or refractory acute lymphoblastic leukemia.

Learn More

Managing Side Effects of Acute Lymphoblastic Leukemia Induction Chemotherapy

With induction chemotherapy, the aim is to put acute lymphoblastic leukemia (ALL) patients into complete remission. However, as these strong drugs kill cancer cells, they produce a number of side effects, some of which can be significant.

Learn More

The Latest Efforts to Preserve the Bladder

In solid tumors affecting organs, efforts have been made to preserve the organ while still eradicating the cancer. The same is true for bladder cancer. Radical cystectomy with pelvic lymph node dissection is a highly morbid procedure, which is often performed in patients who are already elderly and frail.

Learn More

Excitement Around Immune Checkpoint Inhibitors in the Neoadjuvant Setting for Bladder Cancer

The standard treatment for locally invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy. Recently, a number of studies have found that immune checkpoint inhibitors such as pembrolizumab (brand name: Opdivo), atezolizumab (brand name: Tecentriq), and durvalumab (brand name: Imfinzi) in the neoadjuvant setting are equivalent, and sometimes better than chemotherapy alone.

Learn More